Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085488 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00085488 is a Phase 1 study that has completed, run by Dartmouth-Hitchcock Medical Center.
The verdict
NCT00085488, a Phase 1 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.
Interventions
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL therapeutic autologous dendritic cells
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-02 |
| Est. Completion | 2006-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085488
The ClinicalTrials.gov registry entry for NCT00085488 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which autologous tumor cell vaccine is the first listed.
NCT00085488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085488 about?
NCT00085488 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.
What is the current status of trial NCT00085488?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-02. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00085488?
The interventions under investigation include: autologous tumor cell vaccine (BIOLOGICAL), therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00085488?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.